Maggie is a senior editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.
She has a BA in English from Penn State University. You can connect with Maggie on LinkedIn.
Care for Migraine Insufficient in Germany, Online Survey Finds
An online survey of migraineurs in Germany aimed to evaluate their most pressing unmet needs, with data collected on socioeconomic background, medical care experience, acute medication use, and migraine prophylaxis use and experience.
HIIT Shown to Improve Cardiometabolic Risk in Heart Failure
This study enrolled 80 middle-aged patients with stage A heart failure and evaluated them for improvements in several cardiovascular and metabolic risk factors through high-intensity interval training (HIIT) for 1 year and omega-3 fatty acid supplementation.
MBC Outcomes Superior With Trastuzumab Deruxtecan vs Trastuzumab Emtansine
This interim data analysis from the phase 3 DESTINY-Breast03 trial evaluated progression-free survival, overall survival, objective response, and safety between patients with metastatic breast cancer (mBC) progression following previous treatment failure.
Neutral Findings Predominate German Study of CGM Use
This new study from Germany evaluated the use of and satisfaction with continuous glucose monitors (CGMs) since health insurance companies in the country began reimbursement of the technology in 2016 for persons with insulin-dependent diabetes.
HIV-1 Virulence Appears More Potent Among Heterosexual Individuals
This new study evaluated the influence of transmission bottlenecks on HIV-1 infection virulence by comparing outcomes between penile-vaginal intercourse and anal intercourse, and found more severe disease among heterosexual individuals compared with men who have sex with men.
A DCIS Diagnosis Introduces Physical, Emotional Uncertainty for Many Women
This new study focused on the patient perspective following a diagnosis of ductal carcinoma in situ (DCIS), a noninvasive type of breast cancer also referred to as stage 0 or pre-cancer, as well as their concerns over follow-up
Worsened Heart Failure Mortality Seen in Presence of Hyperlactatemia
A new study of patients receiving care for acute heart failure at Rambam Health Care Campus in Haifa, Israel, investigated how their clinical outcomes might be affected by elevated lactate levels and primary acid-base disorders.
Inadequate Testing for CAD Infuses Heart Failure Space
This new analysis of commercial and Medicare Advantage claims from all 50 states investigated utilization of and testing trends for coronary artery disease (CAD) among adults aged 18 and older presenting with new-onset heart failure.
AstraZeneca’s Camille Hertzka: Testing for HRR Mutation Status in mCRPC Helps Inform Risk Profile
Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, discusses why it is important to test for HRR gene mutation status and appropriateness of olaparib use in patients with metastatic castrate-resistant prostate cancer (mCRPC).
Measures of Resistant Hypertension Linked to Worse Outcomes Among Black Adults
A new study has investigated the influence of xanthine oxidase activity and mitochondrial DNA damage–associated molecular patterns on heart failure and cardiac remodeling among Black adults with resistant hypertension.
Possibility of Breast Cancer Overdiagnosis Should Inform Mammography Decisions
This new study of women who underwent mammographic screening for breast cancer at a Breast Cancer Surveillance Consortium facility between 2000 and 2018 investigated potential implications of overdiagnosis.
CROI Abstract Shows Drop in Neurocognitive Deficit Among PLWH
An abstract presented at this year’s Conference on Retroviruses and Opportunistic Infections (CROI) bore out the results of an Italian investigation into a potential link between persons living with HIV (PLWH) taking newer antiretroviral therapies and neurocognitive disorder prevalence.
AstraZeneca's Camille Hertzka Discusses Interim PROpel Trial Findings in mCRPC
Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, discusses principal findings of the PROpel trial, which compared outcomes between olaparib plus abiraterone vs abiraterone alone in men with metastatic castration-resistant prostate cancer (mCRPC).
Further Study Needed to Better Understand HFpEF, Normal NT-proBNP Relationship
This new study investigated the relationship between cardiac function and hemodynamics among individuals presenting with heart failure with preserved ejection fraction (HFpEF) and normal levels of N-terminal prohormone B-type natriuretic peptide (NT-proBNP).
Interferon-α Therapy Bests Donor Lymphocyte Infusion in AML Comparison Study
A new retrospective study of patients with high-risk t(8;21) acute myeloid leukemia (AML) investigated outcomes from 2 therapies following return of minimal residual disease–positive status after allogeneic hematopoietic stem cell transplantation.